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ABSTRACT  15 
Obese individuals are at increased risk of type 2 diabetes 16 
compared to their healthy weight counterparts.  Dietary 17 
fibre, such as alginate, could attenuate glycaemic 18 
disturbances associated with obesity when included in 19 
the diet. 20 
Forty self-reported, healthy males completed this 21 
randomised, single-blinded, controlled, parallel trial to 22 
determine the glycaemic response to a controlled test-23 
lunch of mixed composition following an ionic-gelling 24 
alginate preload drink compared to an acidic-gelling 25 
control. 26 
Individual baseline area under the curve was 52% lower 27 
(P=0.010) and peak glycaemia was 14% lower (P< 28 
0.0005) after the ionic-gelling alginate drink compared 29 
with the control.  Body fatness was a predictor of 30 
postprandial glycaemia however there was no interaction 31 
effect between body fat % and treatment type.   32 
We have shown ionic-gelling alginate can attenuate 33 
glycaemic response to set lunch of mixed composition.  34 
Functional foods that include ionic-gelling alginates may 35 
benefit those with elevated postprandial blood glucose.  36 
KEY WORDS 37 
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1.0 INTRODUCTION  40 
As obesity increases, the incidence of associated co-41 
morbidities rises concomitantly, most dramatically in 42 
relation to body mass index-related diabetes (McPherson 43 
et al., 2007).  Abdominal fatness has been linked with 44 
elevated fasting blood glucose (Rezende et al., 2006).  45 
Pascot et al. (1999) showed visceral adipose tissue 46 
accumulation was accompanied by increased plasma 47 
glucose in the fasted state and after a 75g oral glucose 48 
load in young and middle aged women.  In a six year 49 
prospective study Kriketos et al. (2003) showed baseline 50 
body fatness and increasing fatness over time to be 51 
strong predictors of elevated fasting plasma glucose in 52 
individuals „at-risk‟ of type 2 diabetes  53 
Epidemiological evidence suggests dietary fibres may 54 
have a preventive role in the development of type 2 55 
diabetes (Meyer et al., 2000).  Several mechanisms by 56 
which soluble fibres may modulate glycaemic response 57 
have been proposed (Augustin et al., 2000).  Soluble fibre 58 
ingestion reduces carbohydrate digestion rates, therefore 59 
aiding regulation of postprandial glycaemia (Augustin et 60 
al., 2000; Kimura et al., 1996; Welch, 1994).   61 
 62 
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Soluble fibres have been shown to have beneficial effects 63 
in controlling glycaemia following carbohydrate ingestion 64 
in healthy volunteers (Goñi et al., 2000; Rigaud et al., 65 
1998; Lavin and Read, 1995).  Similarly, fibre-rich foods 66 
(Flammang et al., 2006) and fibre supplementation 67 
(Sierra et al., 2002) have been shown to help attenuate 68 
postprandial glycaemic responses in type 2 diabetic 69 
adults.  Kaline et al. (2007) reviewed the potential 70 
mechanisms by which diets rich in dietary fibre can be 71 
useful in diabetes prevention.  72 
Alginate is an algal polysaccharide found in the cell walls 73 
of certain brown seaweed species.  This fibre has been 74 
used in several relevant human intervention studies.  5.0g 75 
of sodium alginate added to a meal significantly 76 
attenuated postprandial glycaemic response in type 2 77 
diabetics by 31% compared to the control meal 78 
(Torsdottir et al., 1991).  Wolf and colleagues (2002) 79 
demonstrated that 1.5g of sodium alginate, incorporated 80 
into a 100g glucose-based preload drink with an acid-81 
soluble calcium source (to produce an acid-induced 82 
viscosity complex), elicited a non-significant drop in peak 83 
glycaemia and a significant attenuation of incremental 84 
change from baseline area under the curve (AUC) in 85 
healthy, non-diabetic adults compared to a soluble fibre-86 
based control.  Williams et al. (2004) fed a "crispy bar" 87 
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containing 5.5g guar gum and 1.6g sodium alginate to 88 
healthy adults and measured the resultant glycaemic 89 
response compared to an alginate-free bar.  Postprandial 90 
blood glucose excursions were significantly lower at 15, 91 
30, 45, and 120 minutes and the positive incremental 92 
AUC was significantly reduced (by 33%) after 93 
consumption of the enriched “crispy bar” compared to the 94 
alginate-free bar.  Paxman et al. (2008a) reported a 95 
strong positive correlation between change from 96 
individual baseline AUC glycaemia and body fat % when 97 
a hypromellose control preload was ingested prior to a 98 
test lunch.  This positive correlation was not apparent 99 
following an ionic gelling sodium alginate preload, 100 
providing preliminary evidence to suggest that the 101 
enhanced glycaemic response to a meal at higher body 102 
fat could be normalised following ingestion of an alginate 103 
preload identical to the one used in the present study. 104 
Hoad et al. (2004) fed volunteers a strong gelling (high-G) 105 
and a weaker gelling (low-G) alginate meal, a guar-based 106 
meal or a control (without added fibre) and examined the 107 
resultant gastric emptying rates.  In vitro, both alginate 108 
meals formed intragastric gel 'lumps', and in the case of 109 
the strong-gelling alginate, this was reportedly associated 110 
with a feeling of fullness and a reduction in hunger.  Hoad 111 
and colleagues (2004) purport that acid-gelling agents 112 
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such as alginate may be usefully incorporated into 113 
weight-reducing diets/ foods in order to enhance antrum 114 
distension and/ or manipulate nutrient uptake from the 115 
ileum. 116 
Alginate is widely used in the food industry as a thickener, 117 
stabiliser and gelling agent (Brownlee et al., 2005).  Its 118 
constituent sugar residues are D-mannuronic (M) and L-119 
guluronic acid (G).  Homopolymeric G blocks (comprising 120 
diaxial linkages in the 1C4 conformation) can react with 121 
Ca2+ and H+ ions to yield a strong, cross-linked gel 122 
(Brownlee et al., 2005; Seal and Mathers, 2001; Kimura 123 
et al, 1996).  Consequently, the gel strength of alginate 124 
and its consequent biochemical and biophysical 125 
properties are determined by its chemical structure. 126 
Specific alginates and specific alginate formulations are 127 
therefore likely to react differently within the 128 
gastrointestinal milieu. 129 
The primary objective of the present study was to 130 
examine the effect of alginate gelled ionically compared 131 
to acidically (control) on glycaemic response to a 132 
standard meal of mixed composition.  Secondary to this, 133 
we investigated how body fatness affects the postprandial 134 
glycaemic response when subjects ingest the ionic-135 
gelling formulation compared to the acid-gelling control.     136 
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 137 
 138 
2.0 MATERIALS AND METHODS 139 
2.1 Subjects 140 
41 male subjects participated in the study.  Only one 141 
subject was excluded, due to unusually low fasting 142 
glucose levels, leaving complete datasets for 40 143 
participants.  Subjects aged 18 to 65 years were eligible 144 
to take part providing they did not meet any of the criteria 145 
for exclusion which were; type 1 or 2 diabetes, history of, 146 
or current cardiovascular complaints ( or if they had been 147 
fitted with a pacemaker or other implantable electronic 148 
device) or gastrointestinal complaints (such as irritable 149 
bowel syndrome or inflammatory bowel disorder, 150 
dumping syndrome or Cushing‟s syndrome), current fibre 151 
supplement use, use of constipation-causing drugs such 152 
as codeine or morphine, bowel blockage, bowel muscle 153 
weakness or recent food poisoning.  In addition, anyone 154 
with a known allergy to, or intolerance of, the foods or 155 
ingredients used in the experiment was excluded from 156 
taking part, as were vegans (due to the nature of the 157 
foods used).  158 
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Baseline pre-screening took place less than one week 159 
prior to the experimental phase, in which subjects 160 
completed a general health questionnaire and various 161 
anthropometric measures were made.  Height and weight 162 
were recorded (SECA 709 mechanical column scales 163 
with SECA 220 telescopic measuring rod; SECA United 164 
Kingdom, Birmingham) and body mass index (BMI) was 165 
calculated.  Bioelectrical impedance analysis was 166 
undertaken following 5 minutes of supine rest on non-167 
conducting foam matting using a BodyStat 1500 168 
(BodyStat Ltd., Isle of Man, British Isles).  Body fat % was 169 
recorded.  Subjects completed a 51-item Three Factor 170 
Eating Questionnaire (TFEQ; Stunkard and Messick, 171 
1985) to determine eating behaviour across three pre-172 
defined factors.  Mean values for all three factors; 173 
restraint, disinhibition and hunger, were low for the group 174 
as a whole (Stunkard and Messick, 1985).  Subject 175 
characteristics are reported in Table 1.  This study was 176 
approved by the relevant University Ethics Committee 177 
(Ref: FIRC/2006/RE21).  All subjects gave informed 178 
consent to participate.   179 
2.2 Study Design 180 
In this randomised, single-blinded, controlled parallel trial 181 
subjects (n = 40) were split equally either side of the 182 
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median into haptiles by body fatness (lower body fat 183 
group: <16.10%, upper body fat group: ≥16.10%).   184 
Following a 12 hour overnight fast, all subjects consumed 185 
a controlled breakfast at 9am (60g Kellogg‟s® Hint of 186 
Honey Corn Flakes; Kellogg‟s Company GB Limited, 187 
Manchester, 125ml semi-skimmed milk and 200ml „Drink 188 
Fresh‟ orange juice; DCB Foodservice, Herts).  After 189 
breakfast subjects were asked to travel to the laboratory 190 
using motorised transport to minimise energy expenditure.  191 
From breakfast until 11am subjects consumed only 192 
bottled spring water (Highland Spring still natural mineral 193 
water with a sports cap, 2 x 500ml; Highland Spring Ltd, 194 
Perthshire, Scotland) to a maximum volume of 1 litre.  195 
Water consumption was ad libitum but the bottles were 196 
weighed prior to the experiment and at 11am in order to 197 
determine the exact amount consumed before the test-198 
lunch.  Upon arrival at the facility for the experimental day, 199 
subjects were randomly allocated to one of two preload 200 
treatments; an ionic-gelling sodium alginate formulation 201 
(SA) or an acid-gelling excipient free control (EF).  202 
2.3 Preload Formulations and Glycaemia 203 
The SA formulation contained sodium alginate, calcium 204 
carbonate (CaCO3) and buffering agents.  It was 205 
specifically formulated to undergo enhanced ionic 206 
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intragastric gelation upon ingestion.  This is achieved by 207 
mixing sodium alginate with an acid soluble calcium salt.  208 
Post-ingestion solubilisation of calcium salt in acidic 209 
gastric fluid liberates free calcium ions which are then 210 
available to cross-link with the sodium alginate.  The SA 211 
formulation has been described in detail by Paxman et al. 212 
(2008b).  The EF control is identical in composition to SA 213 
with the omission of the CaCO3.  This formulation yields a 214 
gel via acid gelation (in the absence of calcium), resulting 215 
in weaker intra-molecular hydrogen bonded mass. 216 
Prior to preload ingestion, baseline glycaemia (11:45am, 217 
0 minutes) was determined using capillary blood taken 218 
from the finger.  A single use Accu-check® Softclix® Pro 219 
lancing device was used to obtain a single droplet sample 220 
via OneTouch® Ultra® Test Strips with FastDrawTM 221 
design.  The OneTouch® Ultra® Blood Glucose 222 
Monitoring System was used to determine glycaemia 223 
(reference range 1.1 to 33.3mmol/l; Lifescan Inc., Bucks).  224 
Each preload was served at 12:00pm (15 minutes after 225 
baseline glycaemia measurements) in an opaque non-226 
descript plastic cup in standard feeding booths in green 227 
light.  The coloured light masked a very slight colour 228 
difference between preload drinks.  The drinks were 229 
flavoured with vanilla to yield an orosensory match.  230 
Subjects were instructed to drink the entire product.  All 231 
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preloads were consumed within 5 minutes of their initial 232 
hydration with 100ml bottled water.   233 
Following ingestion of the product (12:15pm, 30 minutes 234 
from baseline), glycaemia was again determined 235 
following identical protocol. 236 
2.4 Test-lunch 237 
Volunteers ingested a controlled test-lunch of mixed 238 
composition thirty minutes after consuming the preload 239 
drink (12:30pm, 45 minutes from baseline) in standard 240 
feeding booths in natural light.   The test-lunch consisted 241 
of 300g pre-cooked then chilled penne pasta (Don Mario 242 
100% durum wheat semolina pasta quills', manufactured 243 
by Abbey Foods Ltd, PO BOX 178, Liverpool) and 100g 244 
Sacla Italia ™ vine-ripened tomato and mascarpone stir 245 
through sauce (F.lli Sacla S.p.A. Asti Italy; Sacla UK LTD, 246 
Basil House, 21 London End, Bucks).  This test-lunch 247 
was heated to a temperature of at least 72°C in a 248 
microwave and was served at a temperature of between 249 
60-65°C.  Subjects were instructed to consume the entire 250 
test-lunch and all subjects adhered to protocol. 251 
 252 
The meal provided 57%, 13% and 30% of total energy 253 
from carbohydrate, protein and fat respectively, as 254 
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analysed by NetWISP (version 3.0 for Windows, Tinuviel 255 
Software, Anglesey, UK).  The test-lunch protocol used 256 
here has been described previously (Paxman et al., 257 
2008a). 258 
2.5 Protocol Postprandially 259 
Further measures of capillary glucose were obtained at 260 
90, 120, 150, 180, 210, 240, 270 and 330 minutes from 261 
baseline.  In total, ten capillary blood samples were taken 262 
to determine glycaemia up to 330 minutes from baseline 263 
(270 minutes postprandially).   264 
2.6 Statistical analysis 265 
Blood glucose measures were converted to delta area 266 
under the curve (AUC) using the trapezoid rule with 267 
subtraction of basal values (NCSS; Hintze, 2004, NCSS 268 
and PASS Number Cruncher Statistical Systems, 269 
Kaysville, Utah).  Two-way between groups ANOVAs 270 
were performed in order to identify the main effects of 271 
treatment and body fat haptile and any interaction effects 272 
on glycaemia at each time point, change from individual 273 
baseline AUC glycaemia and peak postprandial 274 
glycaemia (SPSS; version 15.0 for Windows, SPSS Inc., 275 
Chicago, IL, USA).  Graphical presentations were 276 
produced using SPSS (version 15.0 for Windows, SPSS 277 
Inc., Chicago, IL, USA) and Microsoft Excel 2003 278 
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(Microsoft Office, Microsoft Corporation).  Significance 279 
was set at p< 0.05.  Data are presented as mean ± 1 SD. 280 
 281 
3.0 RESULTS 282 
Forty self-reported healthy male subjects (equal numbers 283 
in each treatment arm) successfully completed the 284 
experiment with no deviation from protocol.   285 
3.1 Ionic gelling sodium alginate attenuates the 286 
glycaemic response to a meal 287 
Two-way between groups ANOVAs showed a significant 288 
effect of treatment type on glycaemia at 90 (p< .0005), 289 
150 (p= .003), 180 (p= .021) and 210 (p= .013) minutes 290 
(see Figure 1).  Overall, ingestion of SA compared to EF 291 
resulted in a significant reduction in a mean change from 292 
individual baseline AUC glycaemia (M= 148.43 ± 148.65 293 
vs. M= 312.53 ± 253.60; p= .010) of 52.5% (see Figure 1).   294 
Irrespective of treatment type, subjects in the lower 295 
haptile for body fat % had a reduced mean change from 296 
individual baseline AUC glycaemia (177.68 ± 255.44) 297 
compared to those in the upper haptile for body fat % 298 
(283.28 ± 171.66; p= .065; data not shown) however, this 299 
was not significant and there was no interaction effect 300 
between treatment type and body fat % grouping. 301 
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3.2 Ionic gelling sodium alginate reduces peak 302 
postprandial glycaemia 303 
Preload type failed to affect the timing of peak glycaemia 304 
as shown in Figure 1.  However, Figure 2 shows the 305 
significant 14% lower mean peak postprandial glycaemia 306 
at 90 minutes following SA versus EF (M= 6.06 ± .59 307 
mmol/L vs. M= 6.92 ± .70mmol/L; p< .0005) for the study 308 
group as a whole.  Subjects in the lower body fat haptile 309 
had a lower peak postprandial glycaemia (6.39 310 
± .85mmol/L) than those in the upper body fat haptile, 311 
irrespective of treatment type (6.59 ± .70mmol/L; p= .170; 312 
data not shown) however this was not significant and 313 
there was no interaction effect between treatment type 314 
and body fat % grouping.  315 
3.3 Body fat classification determines the 316 
postprandial glycaemic response to a meal but the 317 
beneficial effects of alginate remain 318 
Irrespective of treatment type, subjects in the upper body 319 
fat haptile had non-significantly elevated peak 320 
postprandial glycaemia and non-significantly greater 321 
mean change from individual baseline AUC glycaemia 322 
compared to those in the lower body fat haptile.  In 323 
addition, body fat % grouping had a significant effect on 324 
delta glycaemia at 120 (p= .005), 150 (p= .012), 180 325 
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(p= .049) and 210 minutes (p= .046) from baseline, with 326 
subjects in the upper body fat haptile having higher mean 327 
glycaemia than those in the lower body fat haptile at 328 
these time points, irrespective of  preload treatment 329 
(Figure 3).   330 
For glycaemia at each time point, change from individual 331 
baseline AUC glycaemia and peak postprandial 332 
glycaemia however, the two-way between-groups 333 
ANOVA showed no interaction effect between treatment 334 
type and body fat % grouping in each case.  Subjects 335 
appeared to respond to the ionic-gelling sodium alginate 336 
(SA) treatment in a similar fashion irrespective of body 337 
fat %.   338 
Examination of the response to treatment type by body 339 
fat % grouping showed the lower body fat haptile on SA 340 
reduced their change from individual baseline AUC 341 
glycaemia by 68.3%, and their peak postprandial 342 
glycaemia by 16.2% compared to the lower body fat 343 
haptile on EF.  A slightly weaker effect was apparent in 344 
the upper body fat haptile on SA who reduced their 345 
change from individual baseline AUC glycaemia by 346 
46.6%, and their peak postprandial glycaemia by 9.7% 347 
compared to those in the upper body fat haptile on the EF 348 
treatment type (Figure 3).  This finding supports our 349 
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previous suggestions relating to altered glycaemic 350 
response and body fatness (Paxman et al., 2008a).  351 
 352 
In summary, glycaemic response to the test-meal was 353 
reduced following ingestion of the ionic-gelling sodium 354 
alginate drink (SA) compared to the acid-gelling 355 
excipient-free formulation (EF) throughout the 330 minute 356 
measurement period.  Body fatness influenced 357 
postprandial glycaemic response but the effect of the 358 
ionic-gelling alginate drink was maintained. 359 
 360 
4.0 DISCUSSION 361 
The literature suggests soluble fibre can alter subjective 362 
hunger and fullness ratings (Peters et al., 2011), gastric 363 
emptying rate and intestinal nutrient absorption, though 364 
the extent and subsequent effect on glycaemia is poorly 365 
established (Wolf et al., 2002; Delargy et al., 1997; 366 
Fairchild et al., 1996).  Contradictory reports are most 367 
likely explained by the type, dose, homogeneity and 368 
physicochemical properties of fibres used, and differing 369 
participant characteristics between studies.  370 
The physiochemical properties of alginate have particular 371 
potential in terms of attenuating postprandial glycaemic 372 
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response and improving diabetic control (Williams et al., 373 
2004; Wolf et al., 2002; Torsdottir et al., 1991).  Highly 374 
viscous solutions are unpalatable; solutions which form 375 
solid gel particles in the gastric lumen may provide a 376 
more feasible alternative for controlling gastric emptying 377 
and nutrient uptake.  In order to establish an optimum 378 
formulation for delivery of a glycaemia-modulating 379 
alginate, the physiological response to ionic- and acid-380 
gelling alginates were compared in males of differing 381 
body fatness.  Physiologic data show greater glucose 382 
intolerance among the obese and numerous prospective 383 
studies support such associations between measures of 384 
obesity and type 2 diabetes risk (Carey et al., 1997).  385 
Such differences are postulated to be connected with 386 
body fatness. 387 
Our data show that the ionic-gelling sodium alginate drink 388 
(SA) reduced early-phase and peak postprandial 389 
glycaemia and flattened the postprandial glycaemic curve 390 
in comparison to the acid-gelling control (EF).  From 391 
baseline to 30 minutes, the EF preload drink resulted in a 392 
slight elevation of blood glucose, most likely due to the 7g 393 
fructose contained within the formulation.  In comparison, 394 
the SA preload treatment elicited no change in glycaemia 395 
during this period despite containing the same amount of 396 
fructose.  The difference between these responses can 397 
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most probably be attributed to the addition of calcium 398 
carbonate in the SA formulation.  The acid-soluble 399 
calcium salt was expected to facilitate intra-gastric ionic 400 
gelation of the drink (Kimura et al., 1996).  When alginate 401 
formulations are pH dependent there is a known time lag 402 
of 25-40 minutes before gelation occurs (Mattes, 2007).  403 
The inhibition of a glycaemic response to the SA 404 
formulation could have resulted from immediate fructose 405 
entrapment, delayed gastric emptying or both.  Torsdottir 406 
et al. (1991) reported delayed glucose delivery and 407 
reduced glycaemic peak in type 2 diabetics by the 408 
addition of alginate to meals.  They attributed this 409 
response solely to delayed gastric emptying, measured 410 
by aspirated radioactive stomach contents.  There is 411 
evidence to suggest alginate ingestion results in 'gel 412 
lump' formation, which alters nutrient transport to the 413 
small intestine (Hoad et al., 2004).  In this study the 414 
glycaemic response to a test-lunch of mixed composition 415 
following the SA drink was consistently lower throughout 416 
the investion, thus it seems likely that nutrients were 417 
captured within the gel matrix to some degree.   418 
Hoad et al. (2004) used serial magnetic resonance 419 
imaging (MRI) to gather in vivo measurements of guar 420 
gum and weak and strong gelling alginates that had been 421 
incorporated into milk-based drinks.  MRI images showed 422 
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heterogeneous distribution of alginate formulations in the 423 
stomach with the formation of 'lumps', compared to the 424 
homogenous distribution of guar gum.  Initial 'gel lump' 425 
formation was observed 10 minutes postprandially, other 426 
'lumps' developed over time, compatible with the pH 427 
decrease normally observed following ingestion of a meal.  428 
In addition, the strong gelling alginate resulted in 429 
significantly increased intragastric gel 'lump' production 430 
compared to the weak gelling.  Data from 'lump' 431 
classification showed liquid filled 'lumps' were formed 432 
predominantly with the strong gelling alginate; the 433 
researchers hypothesise this gel strength is sufficient to 434 
allow layer formation which resist break forces caused by 435 
stomach motion.  436 
There is a prevailing assumption that BMI measurement 437 
is strongly associated with body fatness and consequent 438 
morbidity and mortality (Gallagher et al., 2000).  439 
Increased postprandial blood glucose is independently 440 
related to the risk of cardiovascular disease and all-cause 441 
mortality in newly diagnosed type 2 diabetics.  Some 442 
individuals classified overweight by BMI do not have 443 
high % body fat.  Conversely, others who have normal or 444 
healthy BMIs have a relatively high body fat %.  445 
Individuals who are misclassified by BMI are reportedly 446 
uncommon relative to the UK population as a whole but 447 
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since body fatness is a stronger predictor of increased 448 
fasting glucose than BMI (Kriketos et al., 2003) it is more 449 
appropriate and meaningful to divide subjects in the 450 
present study by body fat %.   In support of this, the 451 
present study clearly shows subjects in the upper body 452 
fat haptile had comparatively elevated early-phase 453 
glycaemic excursion to those in the lower body fat haptile. 454 
 455 
5.0 CONCLUSIONS 456 
We conclude that an ionic-gelling sodium alginate drink 457 
can significantly attenuate postprandial glycaemic 458 
response in self-reported healthy males in comparison to 459 
an acid-gelling control.  This effect persisted in subjects in 460 
both the lower and upper haptiles of body fatness.  The 461 
benefits of optimising glycaemic control through the use 462 
of ionic-gelling sodium alginate products in patients with 463 
morbidity related to body fatness (including type 2 464 
diabetic and metabolic syndrome patients) warrant further 465 
investigation.  466 
  467 
ROLE OF THE FUNDING SOURCE 468 
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 628 
TABLES 629 
Table 1 630 
Subject characteristics 631 
    n Range Mean ± SD 
Age (y)    40 18 – 55  30.03 ± 11.21 
Sodium Alginate Lower BF% 9 20 – 31  23.89 ± 4.05 
  Upper BF% 11 18 – 51  34.55 ± 10.47 
                            TOTAL 20 18 – 51  29.75 ± 9.71 
Excipient Free Lower BF% 11 21 – 32  24.00 ±  3.19 
 Upper BF% 9 19 – 55 38.00 ± 15.94 
 TOTAL 20 19 – 55  30.30 ± 12.78 
BMI (kg/m2)   40 18.6 – 39.4 26.02 ± 4.41 
Sodium Alginate Lower BF% 9 21.7 – 24.7 23.34 ± 1.07 
  Upper BF% 11 22.7 – 35.2 29.07 ± 3.03 
 TOTAL 20 21.7 – 35.2 26.50 ± 3.72 
Excipient Free Lower BF% 11 18.6 – 26.0  22.32 ± 2.33 
  Upper BF% 9 23.0 – 35.6  29.47 ± 4.72 
 TOTAL 20 18.6 – 39.4 25.54 ±  5.06 
Body Fat (BF) %  40 7.1 - 35.6 17.54 ± 7.05 
Sodium Alginate Lower BF% 9 7.1 – 11.9   10.31 ± 1.56 
  Upper BF% 11 16.8 – 31.7 22.58 ± 4.94  
 TOTAL 20 7.1 – 31.7  17.06 ± 7.29 
Excipient Free Lower BF% 11 9.2 – 15.4 12.76 ± 1.82 
  Upper BF% 9 18.1 – 35.6 24.47 ± 5.09 
 TOTAL 20 9.2 – 35.6 18.03 ± 6.96 
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 633 
FIGURE CAPTIONS 634 
Figure 1 635 
Mean delta AUC glycaemia (±1SD) 636 
Following ingestion of the SA preload (solid line, filled 637 
diamonds), mean delta AUC glycaemia was reduced by 638 
52.5% when compared to the EF preload (broken line, 639 
open squares).  There was a significant effect of preload 640 
treatment type on mean delta AUC (p = .010).  In addition, 641 
preload treatment type had a significant effect (*) on 642 
mean delta glycaemia at 90 minutes (p < .0005), 150 643 
minutes (p = .003), 180 minutes (p = .021) and 210 644 
minutes (p = .013).  645 
 646 
Figure 2 647 
Mean peak postprandial glycaemia (±1SD) 648 
There was a significant effect of preload treatment type 649 
on mean peak postprandial glycaemia (SA solid bars; M = 650 
6.06 ± .59 mmol/L compared to EF shaded bars; M = 651 
6.92 ± .70 mmol/L; *p < .0005).   652 
 653 
Figure 3 654 
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Mean delta AUC glycaemia by body fat haptile 655 
When subjects were split by haptiles of body fat % (solid 656 
line = upper body fat haptile, broken line = lower body fat 657 
haptile) there was a significant effect of body fat % 658 
classification (§) on mean delta glycaemia at 120 minutes 659 
(p = .005) 150 minutes (p = .012) 180 minutes (p = .049) 660 
and 210 minutes (p = .046), irrespective of treatment type 661 
(solid diamonds = sodium alginate, open squares = 662 
excipient free). 663 
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